In Monday’s Wall Street session, Mereo Biopharma Group Plc ADR (NASDAQ:MREO) shares traded at $1.72, up 6.83% from the previous session.
MREO stock price is now -31.39% away from the 50-day moving average and -43.92% away from the 200-day moving average. The market capitalization of the company currently stands at $273.48M.
With the price target of $7, JP Morgan recently initiated with Overweight rating for Mereo Biopharma Group Plc ADR (NASDAQ: MREO). On December 06, 2024, Jefferies recently initiated its ‘Buy’ rating on the stock quoting a target price of $7, while ‘Robert W. Baird’ rates the stock as ‘Outperform’
In other news, Scots-Knight Denise, Chief Executive Officer sold 60,046 shares of the company’s stock on Sep 13 ’24. The stock was sold for $253,454 at an average price of $4.22. Upon completion of the transaction, the Chief Executive Officer now directly owns 808,921 shares in the company, valued at $1.39 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 12 ’24, Chief Executive Officer Scots-Knight Denise sold 28,611 shares of the business’s stock. A total of $127,968 was realized by selling the stock at an average price of $4.47. This leaves the insider owning 868,967 shares of the company worth $1.49 million. A total of 16.55% of the company’s stock is owned by insiders.
During the past 12 months, Mereo Biopharma Group Plc ADR has had a low of $1.58 and a high of $5.02. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 8.92, and a quick ratio of 8.92. The fifty day moving average price for MREO is $2.507 and a two-hundred day moving average price translates $3.067075 for the stock.
The latest earnings results from Mereo Biopharma Group Plc ADR (NASDAQ: MREO) was released for 2025-03-31. The company reported revenue of $11.2 million for the quarter, compared to $9.9 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 13.15 percent.
